RS57520B1 - Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r - Google Patents

Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r

Info

Publication number
RS57520B1
RS57520B1 RS20180802A RSP20180802A RS57520B1 RS 57520 B1 RS57520 B1 RS 57520B1 RS 20180802 A RS20180802 A RS 20180802A RS P20180802 A RSP20180802 A RS P20180802A RS 57520 B1 RS57520 B1 RS 57520B1
Authority
RS
Serbia
Prior art keywords
antagonist
administering
methods
atopic dermatitis
treating atopic
Prior art date
Application number
RS20180802A
Other languages
English (en)
Inventor
Marius Ardeleanu
Neil Graham
Jennifer D Hamilton
Stephane C Kirkesseli
Sudeep Kundu
Jeffrey Ming
Allen Radin
Ross E Rocklin
Steven P Weinstein
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233497&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57520(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of RS57520B1 publication Critical patent/RS57520B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
RS20180802A 2012-09-07 2013-09-04 Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r RS57520B1 (sr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261697972P 2012-09-07 2012-09-07
US201261738715P 2012-12-18 2012-12-18
US201361748588P 2013-01-03 2013-01-03
US201361764624P 2013-02-14 2013-02-14
US201361768229P 2013-02-22 2013-02-22
US201361770091P 2013-02-27 2013-02-27
US201361782420P 2013-03-14 2013-03-14
US201361816191P 2013-04-26 2013-04-26
FR1356759 2013-07-10
PCT/US2013/057898 WO2014039461A1 (en) 2012-09-07 2013-09-04 Methods for treating atopic dermatitis by administering an il-4r antagonist
EP13765844.9A EP2892927B1 (en) 2012-09-07 2013-09-04 Methods for treating atopic dermatitis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
RS57520B1 true RS57520B1 (sr) 2018-10-31

Family

ID=50233497

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180802A RS57520B1 (sr) 2012-09-07 2013-09-04 Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r

Country Status (29)

Country Link
US (3) US20140072583A1 (sr)
EP (4) EP2892927B1 (sr)
JP (3) JP6353838B2 (sr)
KR (3) KR102385501B1 (sr)
CN (3) CN118286430A (sr)
AR (1) AR092475A1 (sr)
AU (4) AU2013312868B2 (sr)
BR (1) BR112015005048A8 (sr)
CA (1) CA2883936C (sr)
CY (1) CY1121906T1 (sr)
DK (1) DK2892927T3 (sr)
ES (1) ES2675779T3 (sr)
HK (1) HK1209132A1 (sr)
HR (1) HRP20181227T1 (sr)
HU (1) HUE039387T2 (sr)
IL (1) IL237328B (sr)
LT (1) LT2892927T (sr)
MX (1) MX363193B (sr)
NZ (3) NZ630178A (sr)
PL (1) PL2892927T3 (sr)
PT (1) PT3889181T (sr)
RS (1) RS57520B1 (sr)
RU (2) RU2666630C2 (sr)
SG (2) SG10201701798TA (sr)
SI (1) SI2892927T1 (sr)
TR (1) TR201808181T4 (sr)
TW (3) TWI690328B (sr)
UY (1) UY35013A (sr)
WO (1) WO2014039461A1 (sr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283424B2 (en) 2010-10-06 2023-09-01 Regeneron Pharma Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
EP4324479A3 (en) 2012-08-21 2024-04-24 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
SI2892927T1 (sl) * 2012-09-07 2018-10-30 Regeneron Pharmaceuticals,Inc Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
SI3010539T1 (sl) 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
EP3973987B1 (en) 2014-02-21 2024-01-10 Sanofi Biotechnology Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
JP2017521059A (ja) * 2014-06-17 2017-08-03 ザイクローブ セラピューティクス, インク.Xycrobe Therapeutics, Inc. 機械的に位置合わせされた光学的要素及びその製造方法
TW201628647A (zh) * 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
PT3110848T (pt) * 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
RU2749512C2 (ru) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
EP4420733A2 (en) 2016-02-19 2024-08-28 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4 antagonist
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CA3035202A1 (en) * 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
KR20230006049A (ko) 2016-09-22 2023-01-10 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
CA3031589A1 (en) 2016-09-23 2018-03-29 Genentech, Inc. Uses of il-13 antagonists for treating atopic dermatitis
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
AU2018360999A1 (en) * 2017-10-31 2020-05-14 Oneness Biotech Co. Ltd. Treating IgE-mediated allergic diseases
CA3081751A1 (en) 2017-11-03 2019-05-09 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
WO2019150607A1 (ja) * 2018-01-31 2019-08-08 ＭｅｄｉＤｏｃ Ｓｅａｒｃｈ株式会社 広告提示方法、及び、広告提示システム
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN112823005B (zh) 2018-08-10 2024-08-20 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
WO2020092015A1 (en) * 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
IL289613B2 (en) 2019-08-05 2023-09-01 Regeneron Pharma IL-4R antagonist in combination with a scit regimen to increase immunotherapeutic efficacy and tolerability to a grass-specific allergen
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
US11748800B1 (en) * 2019-09-11 2023-09-05 Life Spectacular, Inc. Generating skin care recommendations for a user based on skin product attributes and user location and demographic data
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
BR112022011098A2 (pt) 2019-12-09 2022-09-20 Sanofi Biotechnology Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados
IL296214A (en) 2020-03-27 2022-11-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an antagonist to il-4r
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
KR20230123993A (ko) 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-31에 결합하는 항체 가변 도메인
US11581084B2 (en) * 2020-12-29 2023-02-14 Kpn Innovations, Llc. Systems and methods for generating an alimentary plan for managing skin disorders
EP4294809A1 (en) * 2021-02-18 2023-12-27 Aclaris Therapeutics, Inc. Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions
WO2023028468A1 (en) 2021-08-23 2023-03-02 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
WO2024076731A1 (en) * 2022-10-06 2024-04-11 Regranion, Llc Methods and compositions for treating hidradenitis suppurativa
US20240141051A1 (en) 2022-11-01 2024-05-02 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3315427B2 (ja) * 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
EP1304115B1 (en) * 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
IL283424B2 (en) 2010-10-06 2023-09-01 Regeneron Pharma Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
RU2453303C1 (ru) * 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
SI2892927T1 (sl) 2012-09-07 2018-10-30 Regeneron Pharmaceuticals,Inc Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R

Also Published As

Publication number Publication date
KR20210095731A (ko) 2021-08-02
JP6353838B2 (ja) 2018-07-04
AU2013312868A1 (en) 2015-03-12
EP4374919A3 (en) 2024-08-21
IL237328B (en) 2020-06-30
RU2018131237A (ru) 2018-10-04
AU2021236538B2 (en) 2023-11-09
SI2892927T1 (sl) 2018-10-30
TW202412839A (zh) 2024-04-01
NZ748451A (en) 2023-04-28
RU2015108073A (ru) 2016-10-27
US20230058395A1 (en) 2023-02-23
KR20150048887A (ko) 2015-05-07
WO2014039461A1 (en) 2014-03-13
CA2883936A1 (en) 2014-03-13
HUE039387T2 (hu) 2018-12-28
CA2883936C (en) 2022-01-11
CN118286417A (zh) 2024-07-05
MX2015002873A (es) 2015-11-13
JP2018154648A (ja) 2018-10-04
AU2019279946A1 (en) 2020-01-16
TR201808181T4 (tr) 2018-07-23
US20170333557A1 (en) 2017-11-23
TWI814575B (zh) 2023-09-01
HK1209132A1 (en) 2016-03-24
PL2892927T3 (pl) 2018-11-30
KR102576903B1 (ko) 2023-09-13
IL237328A0 (en) 2015-04-30
DK2892927T3 (en) 2018-07-16
HRP20181227T1 (hr) 2018-10-05
RU2018131237A3 (sr) 2019-03-14
EP3889181B1 (en) 2024-04-24
AU2018204346A1 (en) 2018-07-05
EP2892927A1 (en) 2015-07-15
TW201414493A (zh) 2014-04-16
UY35013A (es) 2014-03-31
AU2021236538A1 (en) 2021-10-21
TWI699212B (zh) 2020-07-21
NZ630178A (en) 2017-06-30
EP2892927B1 (en) 2018-05-09
CN118286430A (zh) 2024-07-05
BR112015005048A2 (pt) 2017-11-21
JP2023082091A (ja) 2023-06-13
TW202325341A (zh) 2023-07-01
SG11201501011WA (en) 2015-03-30
TWI690328B (zh) 2020-04-11
NZ731864A (en) 2022-07-01
RU2698907C2 (ru) 2019-09-02
LT2892927T (lt) 2018-09-10
AU2013312868B2 (en) 2018-03-22
CY1121906T1 (el) 2020-07-31
EP4374919A2 (en) 2024-05-29
JP2015534548A (ja) 2015-12-03
ES2675779T3 (es) 2018-07-12
PT3889181T (pt) 2024-05-29
RU2666630C2 (ru) 2018-09-11
AU2018204346B2 (en) 2019-10-03
AR092475A1 (es) 2015-04-22
EP3889181A1 (en) 2021-10-06
US20140072583A1 (en) 2014-03-13
CN104995212A (zh) 2015-10-21
JP6637113B2 (ja) 2020-01-29
KR20220049047A (ko) 2022-04-20
KR102122708B1 (ko) 2020-06-17
SG10201701798TA (en) 2017-04-27
AU2019279946B2 (en) 2021-07-01
KR102385501B1 (ko) 2022-04-14
BR112015005048A8 (pt) 2018-01-30
EP3354663A1 (en) 2018-08-01
TW201822816A (zh) 2018-07-01
MX363193B (es) 2019-03-14

Similar Documents

Publication Publication Date Title
HRP20181227T1 (hr) Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
HRP20181963T1 (hr) Postupci za liječenje ili sprječavanje astme primjenom antagonista il-4r
HK1222567A1 (zh) 通過施用 拮抗劑治療鼻息肉症的方法
ZA201906339B (en) Methods for treating pruritus
ZA201407459B (en) Method and apparatus for subscription sharing
EP2851378A4 (en) PROCESS FOR PRODUCING OXYMETHYLENE COPOLYMER
IL278968B (en) Methods for the treatment of atopic dermatitis through the administration of an IL-4R antagonist
HK1209040A1 (en) Methods for treating vestibulotoxicity
IL271284A (en) Methods for treating or preventing asthma by administering an antagonist to -il-r4
EP2736517A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS
HUE046410T2 (hu) Eljárások orrpolipózis kezelésére IL-4R-antagonista beadásával